We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-106.00 | -0.87% | 12,050.00 | 12,036.00 | 12,038.00 | 12,178.00 | 12,010.00 | 12,092.00 | 1,635,146 | 16:35:23 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.34 | 186.61B |
By Cecilia Butini
AstraZeneca PLC on Thursday posted a swing to fourth-quarter profit, though it posted lower revenue due to declining sales of its Covid-19 vaccine Vaxzevria.
The Anglo-Swedish pharma major reported net profit of $901 million, up from a loss of $347 million in the fourth quarter of 2021, when it took a hit from charges related to the acquisition of Alexion Pharmaceuticals.
Operating profit was $1.09 billion in the quarter, up from an operating loss of $292 million the year prior, while earnings per share came in at $0.58 for the period, from a loss per share of $0.22 in the fourth quarter of 2021.
Revenue declined in the quarter to reach $11.21 billion, from $12.01 billion in the fourth quarter of 2021, AstraZeneca said, and product sales fell to $10.80 billion from $11.50 billion the year prior. Lower sales of Covid-19 vaccine Vaxzevria affected total sales in the fourth quarter, and the company said that revenue grew 17% when excluding the vaccine.
Looking ahead at 2023, the company said it expects revenue to increase by a low-to-mid single-digit percentage, and by a low double-digit percentage when excluding Covid-19 medicines. Core earnings per share are expected to increase by a high single-digit to low double-digit percentage, the company said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
February 09, 2023 02:49 ET (07:49 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions